EXPONENT, INC. (EXPO): what the price requires

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/EXPO

Headline

Field	Value
Ticker	EXPO
Company	EXPONENT, INC.
Current price	$63.22/sh
Composition	Engineering and Other Scientific 85% / Environmental and Health 15%

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin needed	12.6%
Operating margin today	22.0%
Margin compression implied	-9.4pp
Implied growth	18.4%
Multiple paid	23x operating income

The operating-margin requirement is derived from the framework's value band at year 12, a separately labeled basis from the headline growth/duration solve.

Solve inputs: computed at a 9.2% cost of capital with 4% terminal growth over a 5-year stage; each 1pp of cost of capital moves the implied operating-profit growth ~6.4pp.

How unusual the bet is: within-range

Reference	Value
vs own history	+0.59σ
cohort percentile (of 225 peers)	54
sustained it ~5 years at this level	39%
implied end-window share	0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	2.69x	5	expensive
Earnings	3.00x	5	expensive
Relative	2.34x	5	expensive
Growth	1.19x	3	expensive

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=18)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$52.93	1.19x	yes	FCF base $0.1B, growth 8% (input: historical growth), terminal g 4.0%, WACC 8.8%, 6yr projection
DCF Exit Multiple	Growth	$64.42	0.98x	yes	Exit EV/EBITDA: 24.3x / 26.3x / 28.3x (bear / base = today's held flat / bull), 6yr
Relative Valuation	Relative	$43.88	1.44x	yes	P/E 21.33x (blended: static sector reference 18x + trailing (TTM) 29x), scenarios: 17.7x / 21.3x / 24.9x (bear / base = reference held flat / bull), EV/EBITDA 16.29x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$23.50	2.69x	yes	BV/sh $6.75, ROE (TTM) 32.2%, ke 9.3%
Two-Stage Excess Return	Asset	$45.88	1.38x	yes	5yr excess ROE then converge to ke=9.3%
Discounted Future Market Cap	Growth	$52.35	1.21x	yes	Rev $0.6B, growth 8% (input: historical growth; tapered), Terminal P/S: 4.4x / 5.3x / 6.1x (bear / base = today's held flat / bull, cap 8x)
Peter Lynch Fair Value	Relative	$25.68	2.46x	yes	EPS $2.14, growth 5% (input: historical EPS growth), PEG=5.45 (Overvalued)
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	$16.25	3.89x	yes	Normalized EBIT (5y avg op income, one-time charges added back) $0.12B × (1−30%) / WACC 8.8% → EPV (no growth)
Residual Income	Asset	$36.20	1.75x	yes	BV $6.75 + 5yr PV of (ROE (TTM) 32.2% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham Number	Asset	$18.03	3.51x	yes	√(22.5 × EPS $2.14 × BVPS $6.75) — Graham's conservative floor
EV/EBITDA Relative	Relative	$26.99	2.34x	yes	EBITDA $0.13B × sector EV/EBITDA 12.0x
FCF Yield	Earnings	$21.08	3.00x	yes	FCF $113.4M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	$15.76	4.01x	yes	SBC-adj FCF $0.09B (FCF $0.11B − SBC $0.02B) capitalized at Kₑ
Ben Graham Formula	Earnings	$34.40	1.84x	yes	EPS $2.14 × (8.5 + 2×5.3%) × (4.4 / 5.3%)
ROIC-Justified P/B	Asset	$4.38	14.43x	yes	BV $6.75 × (ROIC 5.7% / WACC 8.8%)
P/Sales Sector	Relative	$30.07	2.10x	yes	Revenue $0.60B × sector P/S 2.5x
PEG Fair Value	Relative	$17.14	3.69x	yes	EPS $2.14 × (PEG 1.5 × growth 5.3% (input: historical EPS growth)) → PE 8.0x
Earnings Yield	Earnings	$23.14	2.73x	yes	EPS $2.14 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net cash	$118.6m
Net debt / NOPAT (after-tax)	-1.29x (net cash)
Net debt / operating income (pre-tax)	-0.90x (net cash)
Share count CAGR (buyback)	-1.4%
Burning cash	no

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• Exponent is a specialist engineering and scientific consultancy of roughly a thousand PhD-level experts called in for failure analysis, litigation support, and regulatory work, earning a return on equity in the low thirties with no net debt and pricing power that lets it raise billing rates.
• The central risk is valuation versus trajectory: the price pays about 23 times operating income and needs roughly 18.6% annual operating-profit growth for several years, while fiscal 2025 operating income was essentially flat and the firm is headcount-bound.
• Q1 2026 was strong, with revenue up 14% to $166.3 million and EPS up 13% to $0.59, but the durability premium depends on that pace holding, and the firm raised its dividend to $0.31 and added $50 million to its buyback.

Bull Case

An expertise consultancy is one of the harder businesses to value, because its entire asset walks out the door every night and chooses whether to come back. There is no factory, no patent shelf, no installed base; there is a roster of people and a reputation, and the valuation question is really a question about whether both persist. Exponent fits the hard case and then resolves it unusually well. It sells the time of roughly a thousand PhD-level scientists and engineers who are called in when something breaks, a product fails, a structure collapses, a battery catches fire, and someone needs an authoritative, defensible technical answer for a courtroom, a regulator, or a board. The 10-K names why even capable clients still hire it: those "clients that have the capability to perform such services themselves will retain Exponent or other independent consultants because of independence concerns". Independence is a product a client structurally cannot make in-house, which is the closest thing a people business has to a moat.

The economics confirm the reputation is doing real work. The firm earns a return on equity in the low thirties with no net debt, and it raises its billing rates because clients pay for the name on the report, not the hours alone. The 10-K frames the demand backdrop directly, noting that as "advanced materials and electrochemical technologies have become increasingly central to modern devices, understanding how they function - and fail - is essential to ensuring product safety, durability, and competitive performance". That is a structural tailwind: the more complex and electrified the products in the world become, the more failure analysis and litigation work flows to the firms trusted to do it.

The recent quarter showed the model compounding on both levers a consultancy has, rate and volume. First-quarter 2026 total revenue rose 14% to $166.3 million, net income rose 11% to $29.6 million, and EPS rose 13% to $0.59. EBITDA reached $43.1 million, about 28.4% of net revenues, up from 27.3% a year earlier, so the margin widened as the firm grew. Management raised the dividend to $0.31 and expanded the buyback authorization by $50 million, returning the cash a capital-light expertise business throws off rather than hoarding it. For a business whose value is its people and its name, growth with rising margins and rising capital return is the model working.

Bear Case

The moat here is a reputation, and reputations erode quietly before they break visibly. Exponent's edge is that clients trust the name on the report, but every advantage built on trust is exposed to two slow leaks: the experts age out, and the work commoditizes. The firm is fundamentally headcount-bound, with technical staff growing only in the low single digits, which means its growth ceiling is set by how many credentialed experts it can recruit and retain, not by capital it can deploy. The 10-K lists the competitive factors as "technical capability and breadth of services, ability to" serve clients, which is to say the firm competes on talent, and talent is mobile. A rival consultancy, or a client building an in-house team, chips at the edge one hire at a time, and the independence advantage that protects the litigation work does not protect the proactive consulting where in-house teams can substitute.

There is also an emerging substitution risk the price does not obviously credit. Part of Exponent's recent growth came from proactive engagements around AI integration in consumer devices and utility risk management, modern, attractive work, but exactly the kind of analysis where AI tools and well-staffed corporate engineering groups will increasingly compete. The litigation and failure-analysis core is defensible because a courtroom wants an independent human expert; the forward-looking advisory work is less so. If the growth that justifies the multiple comes increasingly from the contestable side of the business rather than the protected side, the durability premium rests on shakier ground than the headline suggests.

That premium is the heart of the bear case, because the price asks for a pace the firm has not been running. At today's level the market pays about 23 times company-wide operating income, which requires operating profit to compound near 18.6% a year for several years. Fiscal 2025 operating income was essentially flat, up just 0.2%, and the first quarter of 2026, strong as it was, grew net income 11%, healthy but well short of the high-teens the price embeds. The methods grounded in what the firm earns and owns, asset value, earnings power, and peer multiples, all read the stock as richly valued; only the forward-growth lens reaches the price, and it reaches it only by crediting years of high-teens compounding. The bet is that a headcount-bound consultancy growing single digits to low double digits re-accelerates and holds a high-teens pace. The bear notes the recent record does not show it yet.

Valuation

The price makes one bet, and it makes it loudly: a durability premium. At about 23 times company-wide operating income, the price requires operating profit to compound near 18.6% a year for several years, a rate above what Exponent has recently delivered and one only a minority of comparable fast-growers have sustained. The demanding part is not any single year's rate; it is the persistence the price asks for, against a firm whose fiscal 2025 operating income was essentially flat and whose growth is capped by how many experts it can add.

The disagreement among the methods is unusually one-sided, and that one-sidedness is the signal. The asset-value, earnings-power, and peer-multiple lenses all read the stock as richly valued, each landing well below the price; only the forward-growth lens reaches today's level. That pattern is what a moat or durability premium looks like in the numbers: the static frames structurally cannot price years of compounding, so when only the growth lens reaches the price, the market is paying for durability the other methods cannot see. The honest read is that on everything the firm has already earned and owns, the stock is expensive, and the entire case for the price is the forward growth holding.

Solvency does not enter the downside here, and that is part of the appeal: Exponent carries net cash of roughly $119 million with no meaningful debt, funds its dividend and buyback from operating cash flow, and shrinks its share count modestly each year. So the decisive variable is growth, not the balance sheet. If the firm can keep adding experts and pushing rates to compound near the high-teens the price implies, the durability premium is earned. If it grows at the single-to-low-double-digit pace its recent record shows, the static methods calling it richly valued are the honest anchor, and the premium has little beneath it.

Catalysts

The first quarter of 2026, reported April 30, was a clear positive. Total revenue grew 14% to $166.3 million, revenues before reimbursements grew 10% to $151.8 million, net income rose 11% to $29.6 million, and EPS rose 13% to $0.59 from $0.52 a year earlier. EBITDA reached $43.1 million, about 28.4% of net revenues, up from 27.3%, so margins widened alongside the growth. Management attributed the strength to proactive engagements, including user-research work for consumer-electronics clients integrating AI into their devices and risk-management work for utilities evaluating asset performance under extreme weather.

The capital-return actions reinforced the print. The company raised its quarterly dividend to $0.31 per share and expanded its share-repurchase authorization by $50 million, while holding about $118.6 million in cash, the steady return of cash a capital-light consultancy generates. Management maintained high-single-digit growth and EBITDA guidance for the year, with headcount additions and realized rate increases as the levers expected to support it.

The forward signals to watch are the firm's two growth levers, billable hours and utilization, against its headcount constraint, since technical staff growth sets the ceiling on how many hours it can ever sell. The mix of work matters too: continued strength in the independent, litigation-driven core is more defensible than growth concentrated in proactive advisory work that in-house teams and new tools can contest. Those trends, plus the trajectory of realized billing rates, are the events most likely to move the thesis.

Peer Cohorts (Per Segment, With Filing Citations)

Engineering and Other Scientific (reported)

• HURN (HURON CONSULTING GROUP INC.)
• (no filing in the citation store)
• FCN (FTI CONSULTING, INC)
• (no filing in the citation store)
• BAH (BOOZ ALLEN HAMILTON HOLDING CORPORATION)
• (no filing in the citation store)
• ACN (Accenture plc)
• (no filing in the citation store)
• KFY (KORN FERRY)
• (no filing in the citation store)

Environmental and Health (reported)

• TTEK (TETRA TECH, INC.)
• (no filing in the citation store)
• ACM (AECOM)
• (no filing in the citation store)
• HURN (HURON CONSULTING GROUP INC.)
• (no filing in the citation store)
• FCN (FTI CONSULTING, INC)
• (no filing in the citation store)

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Exponent Q1 2026 earnings release · Exponent Q1 2026 earnings release, April 30, 2026